ALKERMES | ALKS - Equity Capital And Reserves


ALKERMES reported $1.75B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Malin Corporation EUR 193.2M 75M Dec/2024
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Otsuka Holdings JPY 3.11T 74.63B Mar/2026
Ovoca Bio EUR 1.26M 7.41M Jun/2025
Pfizer USD 90.1B 3.63B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026